AbCellera Biologics (AbCellera Biologics) Change In Receivables : $-72.41 Mil (TTM As of Mar. 2024)

View and export this data going back to 2020. Start your Free Trial

What is AbCellera Biologics Change In Receivables?

AbCellera Biologics's change in receivables for the quarter that ended in Mar. 2024 was $-18.58 Mil. It means AbCellera Biologics's Accounts Receivable increased by $18.58 Mil from Dec. 2023 to Mar. 2024 .

AbCellera Biologics's change in receivables for the fiscal year that ended in Dec. 2023 was $-36.66 Mil. It means AbCellera Biologics's Accounts Receivable increased by $36.66 Mil from Dec. 2022 to Dec. 2023 .

AbCellera Biologics's Accounts Receivable for the quarter that ended in Mar. 2024 was $34.42 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed. AbCellera Biologics's Days Sales Outstanding for the three months ended in Mar. 2024 was 315.52.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. AbCellera Biologics's liquidation value for the three months ended in Mar. 2024 was $391.02 Mil.

AbCellera Biologics Change In Receivables Historical Data

The historical data trend for AbCellera Biologics's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

AbCellera Biologics Change In Receivables Chart

AbCellera Biologics Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Change In Receivables

Get a 7-Day Free Trial

-1.80

-203.02

22.48

106.46

-36.66

AbCellera Biologics Quarterly Data
	Dec18	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Change In Receivables	Get a 7-Day Free Trial															17.18	-32.18	-11.21	-10.44	-18.58

AbCellera Biologics Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-72.41 Mil.

AbCellera Biologics (NAS:ABCL) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

AbCellera Biologics's Days Sales Outstanding for the quarter that ended in Mar. 2024 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	34.419	/	9.954	*	91
=	315.52

2. In Ben Graham's calculation of liquidation value, AbCellera Biologics's accounts receivable are only considered to be worth 75% of book value:

AbCellera Biologics's liquidation value for the quarter that ended in Mar. 2024 is calculated as:

	Liquidation Value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	698.023	-	333.183	+	0.75 * 34.419	+	0.5 * 0.738
=	391.02

AbCellera Biologics Change In Receivables Related Terms

Thank you for viewing the detailed overview of AbCellera Biologics's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.

AbCellera Biologics (AbCellera Biologics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » AbCellera Biologics Inc (NAS:ABCL) » Definitions » Change In Receivables

Comparable Companies

Traded in Other Exchanges

8QQ:Germany

Address

2215 Yukon Street, Vancouver, BC, CAN, V5Y 0A1

Website

https://www.abcellera.com

AbCellera Biologics Inc is an antibody discovery and development engine that's specifically designed to address the barriers of conventional discovery, finding the optimal clinical candidate with greater precision and speed, getting to the clinic and patients sooner. With the integrated AbCellera platform, the company's experts search a wide range of diverse antibodies to select the most effective and developable leads fast and set partners up for enduring success. The company have extensive experience forging partnerships with emerging biotechs and leading pharmaceutical companies. AbCellera leverages proprietary hardware, software, and tools along with the latest data science, to operate as strategic partners and help develop optimized solutions faster for any program.

Executives

John S. Montalbano	director	C/O ABCELLERA BIOLOGICS INC., 2215 YUKON STREET, VANCOUVER A1 V5Y 0A1
Michael R Hayden	director	C/O ASPREVA PHARMACEUTICALS CORPORATION, 1203-4464 MARKHAM STREET, VICTORIA A1 V8Z 7X8
Veronique Lecault	director, officer: Chief Operating Officer	C/O ABCELLERA BIOLOGICS INC., 2215 YUKON STREET, VANCOUVER A1 V5Y 0A1
Thermopylae Holdings Ltd.	10 percent owner	2215 YUKON STREET, VANCOUVER A1 V5Y 0A1
Andrew Booth	officer: Chief Financial Officer	C/O ABCELLERA BIOLOGICS INC., 2215 YUKON STREET, VANCOUVER A1 V5Y 0A1
Andrew Lo	director	C/O ALPHASIMPLEX GROUP, LLC, ONE CAMBRIDGE CENTER, 9TH FLOOR, CAMBRIDGE MA 02142
John Hamer	director, 10 percent owner	PO BOX 14528, RESEARCH TRIANGLE PARK NC 27709-4528
Ester Falconer	officer: Chief Technology Officer	C/O ABCELLERA BIOLOGICS INC., 2215 YUKON STREET, VANCOUVER A1 V5Y 0A1
Hansen Carl L. G.	director, 10 percent owner, officer: Chief Executive Officer	C/O ABCELLERA BIOLOGICS INC., 2215 YUKON STREET, VANCOUVER A1 V5Y 0A1
Tryn Stimart	officer: Chief Legal Officer	C/O ABCELLERA BIOLOGICS INC., 2215 YUKON STREET, VANCOUVER A1 V5Y 0A1
Peter Thiel	director	9200 SUNSET BOULEVARD, SUITE 1110, WEST HOLLYWOOD CA 90069
Dcvc Bio, L.p.	10 percent owner	317 UNIVERSITY AVENUE, SUITE 200, PALO ALTO CA 94301
Dcvc Bio Gp, Llc	10 percent owner	270 UNIVERSITY AVENUE, PALO ALTO CA 94301
Zachary Bogue	10 percent owner	270 UNIVERSITY AVENUE, PALO ALTO CA 94301
Matthew Ocko	10 percent owner	270 UNIVERSITY AVENUE, PALO ALTO CA 94301